Abstract: A system includes a computer that is programmed to receive one or more media streams, each from a respective one of a one or more media capture devices, and to receive, from a client device, for each of the one or more media streams, state data including at least one of an active and a potential state of the media stream. The computer is further programmed to disconnect from the client device, and then, upon reconnecting to the client device, to provide at least one of the media streams and the state data to the client device.

Abstract: A wellbore system includes a slip hanger arranged within a wellbore component, the slip hanger having a mechanical receptacle formed in a face of the slip hanger. The wellbore system also includes an adapter configured to couple to the slip hanger, the adapter having one or more engagement members arranged to engage the mechanical receptacle, wherein the one or more engagement members extend into the mechanical receptacle to secure the slip hanger to the adapter.

Abstract: A wellbore system includes an adapter configured to couple to a downhole component. The wellbore system also includes a retrieval tubular, having a bore extending therethrough. The wellbore system further includes a piston assembly coupled to the retrieval tubular, wherein the bore is in fluid communication with a cavity of the piston assembly. The wellbore system includes a stem configured to couple to a casing section, the casing section being supported by a hanger. The wellbore system also includes a sleeve forming at least a portion of the piston assembly, the sleeve configured to couple to the adapter such that, responsive to a force applied by the piston at the casing section, the sleeve applies an upward force to the adapter.

Abstract: Described herein is a method for obtaining a selective estrogen receptor degrader, and compounds used in preparing the selective estrogen receptor degrader.

Abstract: A system includes a computer that is programmed to receive one or more media streams, each from a respective one of a one or more media capture devices, and to receive, from a client device, for each of the one or more media streams, state data including at least one of an active and a potential state of the media stream. The computer is further programmed to disconnect from the client device, and then, upon reconnecting to the client device, to provide at least one of the media streams and the state data to the client device.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: A system includes a computer that is programmed to receive one or more media streams, each from a respective one of a one or more media capture devices, and to receive, from a client device, for each of the one or more media streams, state data including at least one of an active and a potential state of the media stream. The computer is further programmed to disconnect from the client device, and then, upon reconnecting to the client device, to provide at least one of the media streams and the state data to the client device.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and another inhibitor (such as a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor), along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Abstract: Salts of Compound A and forms described herein are estrogen receptor alpha modulators. Such salts and/or forms can be are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Various arrangements for debugging a hung thread of a software application are presented. A thread monitor module may be executed that monitors for any hung threads within a plurality of executing threads. A monitoring initialization message may be received that initiates thread monitoring of a thread. In response to the monitoring initialization message, tracking of the thread may be commenced by determining whether an update message for the thread has been received within an amount of time allotted for the update message to be sent. If the update message is not received, the thread may be identified as hung. Debugging information generated in response to identifying the hung thread may be used for creating an improved version of the software application that prevents the hang.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.

Abstract: A wellbore system includes an adapter configured to couple to a downhole component. The wellbore system also includes a retrieval tubular, having a bore extending therethrough. The wellbore system further includes a piston assembly coupled to the retrieval tubular, wherein the bore is in fluid communication with a cavity of the piston assembly. The wellbore system includes a stem configured to couple to a casing section, the casing section being supported by a hanger. The wellbore system also includes a sleeve forming at least a portion of the piston assembly, the sleeve configured to couple to the adapter such that, responsive to a force applied by the piston at the casing section, the sleeve applies an upward force to the adapter.

Abstract: A wellbore system includes a slip hanger arranged within a wellbore component, the slip hanger having a mechanical receptacle formed in a face of the slip hanger. The wellbore system also includes an adapter configured to couple to the slip hanger, the adapter having one or more engagement members arranged to engage the mechanical receptacle, wherein the one or more engagement members extend into the mechanical receptacle to secure the slip hanger to the adapter.

Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.

Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).

Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.